Compare · BTTC vs GILD
BTTC vs GILD
Side-by-side comparison of Black Titan Corporation (BTTC) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTTC and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 32965.3x BTTC ($5.9M).
- Over the past year, BTTC is down 92.7% and GILD is up 26.9% - GILD leads by 119.6 points.
- GILD has been more active in the news (5 items in the past 4 weeks vs 1 for BTTC).
- GILD has more recent analyst coverage (25 ratings vs 0 for BTTC).
- Company
- Black Titan Corporation
- Gilead Sciences Inc.
- Price
- $0.37-9.64%
- $156.22-0.76%
- Market cap
- $5.9M
- $195.13B
- 1M return
- +1.41%
- +3.48%
- 1Y return
- -92.67%
- +26.88%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest BTTC
- SEC Form 6-K filed by Black Titan Corporation
- DeFi-as-a-Service, Lending-as-a-Service and the Bank-Issued Rails
- SEC Form 6-K filed by Black Titan Corporation
- SEC Form 6-K filed by Black Titan Corporation
- Black Titan Corporation Announces Receipt of Nasdaq Non-Compliance Notice
- Black Titan Corporation Announces Full Conversion of Its Outstanding Convertible Note
- SEC Form 6-K filed by Black Titan Corporation
- SEC Form 6-K filed by Black Titan Corporation
- Stablecoin Payments Shift From Supply Growth to Network Utilization and Machine-Native Commerce
- Institutional Digital Asset Infrastructure: Distribution Layer Expansion and CEX-to-DeFi LaaS Convergence
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)